Previous 10 | Next 10 |
CUPERTINO, Calif. , Sept. 17, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it has completed the Phase 2a clinical trial of its lead product candidate, DUR-928, in patients with alcoholic hepatitis (AH). The final enrollment for the trial consists...
Gilead Sciences' ( GILD +2.3% ) decision to advance development of an investigational long-acting HIV injectable based on DURECT's ( DRRX +1.7% ) SABER technology triggers a $10M milestone payment to the latter under their license agreement inked in July. More news on: Gilead Scien...
CUPERTINO, Calif. , Sept. 9, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that further development of a long-acting injectable HIV investigational product utilizing DURECT's SABER ® technology has triggered a $10 million milestone payment from Gile...
Three small-cap drugmakers with very different paths to the big leagues recently drew cheers from a large investment bank. In fact, the bank predicted gains of 181% or better from their previous closing. Grizzled investors know that biotech stocks rarely live up to eye-popping price tar...
Shares of Durect (NASDAQ: DRRX) , a commercial-stage biopharmaceutical company with numerous drugs in development , rose as much as 12% in early morning trading on Friday. The stock was up about 10% as of 11:30 a.m. EDT. Investors can thank Elemer Piros, an analyst at Cantor Fitzgerald...
DocuSign (NASDAQ: DOCU ) +23% on Q2 results and analyst upgrade . More news on: DocuSign, Inc., Neon Therapeutics, Inc., Telenav, Inc., Stocks on the move, Read more ...
Durect (NASDAQ: DRRX ) initiated with Overweight rating and $5 (201% upside) price target at Cantor Fitzgerald. More news on: DURECT Corporation, Ekso Bionics Holdings, Inc., Kadmon Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
CUPERTINO, Calif. , Sept. 4, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment Conference, sponsored by H. C. Wainwright, at the Lotte N...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) declined again last week, falling from 3,323.71 points on Monday’s (July 29) open to 3,282.81 points as of 1:22 p.m. EDT on Friday (August 2). Over the course of the week, a number of top companies released pivotal Q2 2019 earnings, i...
DURECT Corporation (DRRX) Q2 2019 Results Earnings Conference Call August 01, 2019, 04:30 PM ET Company Participants Mike Arenberg - CFO Jim Brown - President and CEO Conference Call Participants Adam Walsh - Stifel Ed Arce - H.C. Wainwright and Co. François Briseboi...
News, Short Squeeze, Breakout and More Instantly...
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis PR Newswire DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial CUPERTINO, Calif. , May ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 171.6% to $0.1657 on volume of 180,907,472 shares AMC Entertainment Holdings Inc. Class A (AMC) rose 84.4% to $9.57 on volume of 174,658,682 shares Plug Power Inc. (PLUG) rose 45.9%...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update PR Newswire - FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Ea...